Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ISIS 757456 · 2 trials · 2 indications
The baseline for plasma AGT was defined as the average of all values prior to the first dose of study drug.
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | Participants received ISIS 757456-matching placebo, subcutaneous (SC) injection, once-weekly for 8 weeks and an additional loading dose on Day 3. |
| ISIS 757456 | EXPERIMENTAL | Participants received ISIS 757456 80 mg, SC injection, once-weekly for 8 weeks and an additional loading dose on Day 3. |
| ISIS 757456 80 mg | EXPERIMENTAL | ISIS 757456 80 mg injected SC once weekly for up to 6 weeks and an additional loading dose of 80 mg on Day 3. |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | ISIS 757456-matching placebo solution administered as SC injection. |
| ISIS 757456 | DRUG | ISIS 757456 administered as SC injection. |
Inclusion criteria: * Males or females aged 18-75 inclusive and weighing ≥ 50 kilograms (kg) at the time of informed consent * Females must be non-pregnant and non-lactating, and either surgically sterile or post-menopausal * Males must be surgically sterile or, abstinent or, if engaged in sexual r...
ISIS 757456, also known as IONIS-AGT-LRx, is an investigational antisense inhibitor being developed for the treatment of mild hypertension and hypertension. It is administered subcutaneously and is intended for hypertensive participants with controlled blood pressure. The drug is currently in Phase 2 clinical development.
ISIS 757456 targets angiotensinogen (AGT), as indicated by its alternative name IONIS-AGT-LRx. It is an antisense inhibitor designed to reduce the production of angiotensinogen, a protein involved in blood pressure regulation. By targeting AGT, the drug aims to lower blood pressure in patients with hypertension.
ISIS 757456 is developed by Ionis Pharmaceuticals, Inc., a biopharmaceutical company traded under the ticker IONS. The company is conducting clinical trials to evaluate the safety, tolerability, and efficacy of this antisense inhibitor in patients with hypertension.
ISIS 757456 is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Two Phase 2 trials have been completed, both focusing on patients with hypertension, including those with mild hypertension and controlled blood pressure.
ISIS 757456 has been studied in two completed Phase 2 clinical trials. The first, NCT03714776, assessed the drug in 25 participants with mild hypertension. The second, NCT04083222, enrolled 26 participants with hypertension. Both trials were conducted in the United States and were randomized, double-blind, and placebo-controlled.
Yes, ISIS 757456 is the same as IONIS-AGT-LRx. The drug is referred to by both names in clinical trial records. IONIS-AGT-LRx is the more descriptive name, indicating its target angiotensinogen and its antisense mechanism. Both names refer to the same investigational compound developed by Ionis Pharmaceuticals.